{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of November 2020): No"],"condition":["Gastrointestinal Neoplasms","Colorectal cancer","Gastrointestinal Cancer","Tumor vaccine therapy","Gastric cancer","Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer.","Esophageal cancer"],"disease":["Gastrointestinal Neoplasms","Tumor Vaccine Therapy","Gastric Cancer","Gastrointestinal Cancer","Colorectal Cancer","Esophageal Cancer","Patients With Histologically Confirmed Diagnosis Of Colorectal Carcinoma (left-sided Or Rectal), Esophageal Carcinoma, Or Gastric Cancer."],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2324408"],"location":["Germany"],"study_start_month":["11"],"keyword":["Anti-PD-1","TMV-018","Flucytosine","Oncolytic virus","5-FC"],"repository":["ECRIN MDR"],"study_status":["Withdrawn"],"additional_accession":[]},"is_claimable":false,"name":"A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract","description":"This study aims to determine the safety and tolerability of TMV-018 when given alone or in combination with the prodrug 5-Fluorocytosine (5-FC) or an anti-PD-1 checkpoint inhibitor in patients with gastrointestinal tumors. Furthermore, the maximum tolerated dose (MTD) and recommended Phase II dose of TMV-018 shall be determined.","dates":{"creation":"2020-11-15"},"accession":"2324408","cross_references":{"ClinicalTrials___gov":["NCT04195373"],"EU Clinical Trials Register":["2019-003550-88"]}}